PK/PD assessment of posaconazole enteric-coated tablets in liver transplantation patients in intensive care unit

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200056400

Enrollment

Unknown

Registered

2022-02-05

Start date

2022-05-31

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Interventions

TDM group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years, male or female; 2. Liver transplant patients; 3. Patients with high risk factors of fungal infection; 4. Use posaconazole enteric-coated tablets for prevention invasive fungal disease.

Exclusion criteria

Exclusion criteria: 1. Patients is allergic to posaconazole; 2. Patients who use of drugs that can significantly change the pharmacokinetic characteristics of posaconazole, such as phenytoin, rifampin, and liver drug enzyme inducers; 3. Patients who cannot take oral medication, such as patients who use ECMO and other medical devices, coma, and shock.

Design outcomes

Primary

Measure	Time frame
Safety;Efficacy;Posaconazole blood concentration;	—

Countries

China

Contacts

Public ContactWang Taotao

The First Affiliated Hospital of Xi’an Jiaotong University

tao50125@163.com+86 150 0293 2036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026